National Hospital for Tropical Diseases, Hanoi, Vietnam
13
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Role: collaborator
Prediction of Infectious Diseases in LMICs Using Electronic Health Record Data
Role: collaborator
Making an Early Diagnosis of Talaromycosis Using a Novel Antigen Test
Role: collaborator
Convalescent Plasma for COVID-19 Patients
Role: collaborator
Convalescent Plasma for COVID-19 Patients (CPCP)
Role: collaborator
Implementation of CRP Point of Care Testing in Primary Care to Improve Antibiotic Targeting in Respiratory Illness (ICAT)
Role: collaborator
The Vietnam Chloroquine Treatment on COVID-19
Role: collaborator
Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report
Role: lead
Vietnam Cryptococcal Retention in Care Study Version 1.0
Role: lead
Vietnam Cryptococcal Retention in Care Study - Version 2.1
Role: lead
C Reactive Protein (CRP) Intervention to Reduce Inappropriate Antibiotic Prescriptions in the Primary Healthcare Setting
Role: collaborator
Human Suis and Pig Diseases in Northern Vietnam
Role: collaborator
MALDITOF Versus Routine Clinical Microbiology for Identifying Pathogens; a Randomized Diagnostic Trial
Role: collaborator
All 13 trials loaded